Future iterations of vaccine buyers' and distribution clubs as well as public vaccine development efforts should work towards reducing all aspects of public health risk rather than privileging its corporate financial aspects. This will include reassessing the interplay of aid and corporate subsidies in global health.
No takes yet. Share an insight, caveat, or question.
Felix Stein (2021) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: